Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma

M. V. Kopp, E. Hamelmann, S. Zielen, W. Kamin, K. C. Bergmann, C. Sieder, S. Stenglein, S. Seyfried, U. Wahn